Back to All Events

Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee

The Committee will discuss new drug application (NDA) 210136, buprenorphine subcutaneous injection, submitted by Braeburn Pharmaceuticals, Inc., for treatment of opioid dependence.